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Atopy, the excessive production of speciﬁc IgE in response to
common environmental allergens, is believed to be an important
causative factor for asthma, irrespective of age at onset. A theoret-
ical paradigm has evolved in which allergen exposure produces
allergic sensitization and continued exposure leads to clinical
asthma through the development of airway inﬂammation, bron-
chial hyperresponsiveness, and reversible airﬂow obstruction. In
general, however, the genes controlling IgE levels have surprisingly
little overlap with the genes mediating asthma susceptibility; some
people insist that atopy is secondary to asthma, not a primary
driver of the disease.1 Genetic studies of children with atopic
dermatitis have shown that defects in barrier proteins such as Filag-
grin commonly predispose individuals to the disease, indicating
that increases in IgE responsiveness may be secondary to barrier
failure. Analogically, the integrity of the airway epithelium in pa-
tients with asthma is often disrupted with loss of epithelial
cellecell contact. Because many of the recently identiﬁed suscepti-
bility genes for asthma are expressed in airway epithelium, changes
at the airway epithelial barrier may play a central role in secondary
sensitization to allergens.
We recently found that the CDHR3 variant (Cys529/Tyr), that
supports efﬁcient human rhinovirus C entry and replication, was
associated speciﬁcally with a phenotype of adult asthma character-
ized by atopy, early-onset, and airﬂow obstruction.2 We also con-
structed a multi-SNP genetic risk score (GRS) for airﬂow
obstruction using genotype information for 16 genes associated
with lower FEV1/FVC in a genome-wide association study (GWAS)
of Japanese populations as well as in previous GWASs of non-
Japanese populations3,4; an increased GRS, which may reﬂect
deregulated lung growth or development, was strongly associated
with a particular phenotype of asthma characterized by atopy,
early-onset, and airﬂow obstruction. Interestingly, both genetic fac-
tors, the CDHR3 variant and the GRS for airﬂow obstruction, were
not associated with atopy. Meanwhile, our previous study showed
that loci showing strong association to IgE had minimal effects on
asthma.5
Given that these ﬁndings suggest that allergic sensitization in
asthma may be an inconstant secondary effect of asthma instead
of its cause, we used a Mendelian randomization strategy to
examine whether atopy is a cause of asthma, or a consequence of
it. Alleles for genetic variants are randomly inherited at meiosis.
Mendelian randomization analysis uses these genetic variants to
test whether a particular risk factor is causal for a disease outcome.Peer review under responsibility of Japanese Society of Allergology.
https://doi.org/10.1016/j.alit.2017.10.005
1323-8930/Copyright © 2017, Japanese Society of Allergology. Production and hosting by Else
licenses/by-nc-nd/4.0/).Multiple genetic variants based on GWAS data increases the power
of Mendelian randomization.6 Here, we initially conducted a GWAS
for atopy using 967 healthy adults (541 were atopic).2,3 We deﬁned
atopy as a positive IgE response to at least 1 of 14 common inhaled
allergens (Supplementary Table 1). We tested for gene-level repli-
cations across 25 genes that were identiﬁed in 2 previous non-
Japanese GWASs7,8 as being associated with atopy and with P-
values less than 5.0  108.4 When we selected the top SNPs with
the strongest statistical evidence of association with atopy in
each region extending ±100 kb from each candidate gene, 20 out
of the 25 genes were nominally associated (P < 0.05) with atopy
in our GWAS (Supplementary Table 1).
In addition to the 967 healthy adults and 216 patients with
asthma for whom we already had GWAS genotyping, we used the
TaqMan allele-speciﬁc ampliﬁcation method to genotype a further
533 healthy adults and 325 adults with asthma for these 20 SNPs.2
They were all recruited in the Tsukuba area, Japan.2,3 For 1 of the
SNPs, PVT1-MYC (rs6470586), wewere unable to obtain reliable ge-
notype information due to insufﬁcient ampliﬁcation and, therefore,
we calculated the atopy GRS using the genotype information of the
remaining 19 SNPs in a total of 1500 healthy adults (883 were
atopic) and 541 adults with asthma (391 were atopic)
(Supplementary Table 2). The GRS, which combines the modest ef-
fects of multiple SNPs into a single variable, is calculated as the
weighted sum of the product of the OR for risk alleles using the for-
mula
GRSi ¼
X19
k¼1
ORkRAk
where GRSi is the atopy GRS for individual i; ORk is the OR of SNPk
as the weight of each risk allele derived from our GWAS for atopy;
and RAk is the number of risk alleles for SNPk (0, 1, or 2).
In this population, atopy was strongly associated with asthma
(OR ¼ 1.82, P ¼ 3.40  108). In non-asthmatic healthy adults,
GRS was highly associated with atopy (GRS [SD] 26.9 [113] and
26.4 [1.05] for 883 atopic and 617 non-atopic individuals, respec-
tively, P ¼ 2.64  1016). However, despite the strong association
of GRS with atopy, GRS was not associated with asthma
(P ¼ 0.31). Furthermore, the extent of the association between
atopy and asthma did not change after adjustment for GRS
(OR ¼ 1.89, P ¼ 1.07  108) and GRS levels in patients with atopic
asthma were similar to those of non-atopic asthma, and were
signiﬁcantly lower than those of atopic healthy adults (Fig. 1), sug-
gesting that the signiﬁcant association between atopy and asthma
was not entirely mediated by the GRS effect. These results indicated
that the Mendelian randomization technique revealed no evidence
of a causal link between atopy and asthma, which is consistent withvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. The GRS levels according to the presence or absence of atopy and asthma. When
we compared the levels of GRS according to the 4 groups (atopic and non-atopic
healthy adults, adults with atopic and non-atopic asthma), the highest levels of GRS
was found in atopic healthy adults. Error bars indicate 95% conﬁdence intervals.
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asthma in this population. Allergen-speciﬁc IgE responsiveness is
a phenotypically heterogeneous condition and IgE sensitization to
Japanese cedar is less related to asthma9; however, we did not
see any difference in the results after we repeated the analyses by
excluding a Japanese cedar-speciﬁc IgE response from the deﬁni-
tion of atopy.
As the levels of GRS for the 391 patients with atopic asthma
were signiﬁcantly higher than those for the 617 non-atopic, non-
asthmatic healthy individuals (Fig. 1), we calculated the population
attributable risk fraction (PARF) using the formula
PARF ¼ PðEÞðOR  1Þ=½1þ PðEÞðOR  1Þ
where P(E) is the probability of having the highest GRS than in-
dividuals in the lower quintile of the risk score distributionFig. 2. Odds ratios for association between the atopy GRS and atopic asthma across the
GRS quintiles. For each atopy GRS quintile, odds ratios for the development of atopic
asthma were obtained using 391 patients with atopic asthma and 617 non-atopic
non asthmatic healthy individuals. The odds ratio for comparison between the 5th
and 1st quintiles was 2.36 (95% CI ¼ 1.57e3.54, *P ¼ 2.9  105). The odds ratio for
comparison between the 5th and 1st to 4th quintiles was 1.99 (95% CI ¼ 1.46e2.72,
P ¼ 1.2  105), which was used for the estimation of proportion of atopic asthma cases
attributable to the GRS.(P(E) ¼ 0.2), and OR refers to the odds of having atopic asthma for
individuals in quintiles 5 of the GRS distribution as compared to the
odds of having atopic asthma for individuals in the lower quintile
(quintiles 1 to 4) of the GRS distribution (Fig. 2). The estimated
proportion of atopic asthma cases attributable to genetic suscep-
tibility to atopy or GRS in the highest quintile was 16.6%.
In this study, we do not intend to argue that atopy does not play
an important role in the pathobiology of atopic asthma; acquired
allergic sensitization could play a role in maintaining chronic
asthma by setting off the allergic inﬂammatory cascade and subse-
quent disease progression. Nevertheless, the danger is that overem-
phasis on a particular theoretical paradigm for which the evidence
is less substantial than is commonly assumed may have led to an
under-recognition of, and insufﬁcient research into, other potential
novel causal pathways, such as the susceptibility to viral infection
or impaired lung growth that underlie atopic asthma.10
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